Every material Form 8-K vTv Therapeutics Inc. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
vTv Therapeutics reported a third-quarter 2026 net loss attributable to shareholders of $11.6 million, or $0.94 per share, up from $8.7 million, or $1.08 per share, a year earlier, with no revenue in either quarter. Research and development and general and administrative expenses both rose, and cash fell to $77.2 million from $88.9 million at December 31, 2025, which the company says is sufficient to fund operations well through the Phase 3 CATT1 topline readout expected in mid 2027.
Q3 2026 net loss attributable to vTv shareholders was $11.6 million ($0.94 per share), compared with $8.7 million ($1.08 per share) in Q3 2025.
R&D expenses rose to $7.5 million from $7.0 million; G&A expenses rose to $4.9 million from $3.7 million.
Cash and cash equivalents were $77.2 million at September 30, 2026, versus $88.9 million at December 31, 2025.
Nine-month 2026 revenue was $36.8 million, compared with none in the prior-year period, per the statement of operations.
vTv Therapeutics reported second-quarter 2026 results with no revenue in the quarter, and its net loss attributable to shareholders grew to $13.1 million from $6.0 million a year earlier. Higher R&D spending on the Phase 3 CATT1 trial drove the increase, and the company said its cash should fund operations through the anticipated CATT1 topline data readout.
Q2 2026 net loss attributable to vTv shareholders was $13.1 million, or $1.05 per share, versus $6.0 million, or $0.92 per share, in Q2 2025.
R&D expenses rose to $8.8 million from $4.1 million, mainly due to investment in the Phase 3 CATT1 trial.
Cash and cash equivalents were $86.6 million at June 30, 2026, down from $88.9 million at December 31, 2025.
Six-month results included $36.8 million of revenue and net income of $11.1 million, or $0.89 per basic share.
On May 13, 2026, vTv Therapeutics filed a prospectus supplement to increase the number of Class A common shares offered under its previously announced at-the-market (ATM) sales program to the full amount provided for under that program. The company also filed a Dechert LLP legal opinion on the legality of the shares issuable under the program, incorporated into its effective Form S-3 shelf registration statement.
Prospectus supplement filed May 13, 2026 raises Class A common stock offered under the ATM Program to the full amount provided for.
Dechert LLP legal opinion on the legality of the shares is filed as Exhibit 5.1.
The filing does not state the number of shares or the dollar amount involved.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every vTv Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →